Fougera Pharmaceuticals, LLC FDA Inspection Record
Fougera Pharmaceuticals, LLC is an FDA-registered facility (FEI 2432435) located in Melville, NY, US. Registered operations: ANALYSIS. RegDataLab tracks 12 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Dec 8, 2023: No Action Indicated (NAI)
- Inspections on record
- 12 (11 VAI, 1 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 27, latest Mar 2, 2017
- Import refusals
- 8
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Dec 8, 2023 | No Action Indicated (NAI) | No citations listed |
| Aug 10, 2022 | Voluntary Action Indicated (VAI) | Reactive/Additive/Absorptive Containers/Closures (21 CFR 211.94(a)) Microbiological testing (21 CFR 211.165(b)) Scientifically sound laboratory controls (21 CFR 211.160(b)) |
| Aug 8, 2019 | Voluntary Action Indicated (VAI) | Written procedures not established/followed (21 CFR 211.67(b)) |
| May 29, 2018 | Voluntary Action Indicated (VAI) | Procedures not in writing, fully followed (21 CFR 211.22(d)) |
| Nov 10, 2016 | Voluntary Action Indicated (VAI) | No citations listed |
| Dec 23, 2014 | Voluntary Action Indicated (VAI) | SOPs not followed / documented (21 CFR 211.100(b)) |
| Oct 31, 2013 | Voluntary Action Indicated (VAI) | Cleaning / Sanitizing / Maintenance (21 CFR 211.67(a)) Written in-process control procedures (21 CFR 211.110(a)) |
| Nov 16, 2012 | Voluntary Action Indicated (VAI) | Scientifically sound laboratory controls (21 CFR 211.160(b)) |
| Jun 15, 2012 | Voluntary Action Indicated (VAI) | No citations listed |
| Feb 9, 2011 | Voluntary Action Indicated (VAI) | No citations listed |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Mar 2, 2017 | Class II | D-0612-2017 | Desonide Ointment, 0.05%, NET WT 60 grams tubes, Rx only, E. FOUGERA & CO. A division of… Labeling: Label Mixup; Unit boxes labeled as Desonide Ointment 0.05% may contain tubes of Desonide Ointment labeled as Ketoconazole Cream |
| Aug 28, 2014 | Class II | D-0245-2015 | FLUOCINONIDE GEL USP, 0.05%, Rx only, For External Use Only, Not For Ophthalmic Use, a)… Failed Stability Specifications: The lots of Fluocinonide Gel USP, 0.05% recalled, may not meet the requirements for residual solvents as… |
| Jul 3, 2014 | Class III | D-1440-2014 | Triamcinolone Acetonide Lotion USP, 0.1%, 60 mL Bottle, Rx Only, For Dermatologic Use… and 1 more product Failed PH Specifications: It has been determined that the pH of the lots recalled, may not meet specification at expiry. |
| Jan 29, 2014 | Class III | D-1152-2014 | Triamcinolone Acetonide Cream USP, 0.1%, Net Wt 80 grams per tube, Rx only, E. Fougera &… Labeling: Label Error on Declared Strength: There is a misprint on the end flap which read 01% rather than 0.1%. |
| Nov 18, 2013 | Class III | D-1044-2014 | KETOCONAZOLE CREAM, 2%, 30 gram tube, Rx only, E. FOUGERA & CO., A division of Fougera… Failed Impurities/Degradation Specifications: Out-of-Specification degradant results. |
| Jul 18, 2012 | Class III | D-241-2013 | Fougera Ketoconazole Cream 2%, 15g tube, Rx only, Labeled with E. Fougera & Co., a… Failed Impurities/Degradation Specifications: Ketoconazole Cream 2% is the subject of a voluntary drug recall by Fougera due to an Out Of… |
| Aug 1, 2011 | Class III | D-860-2011 | Ciclopirox Shampoo, 1%, For Topical Use only, 120 mL bottle, Rx only, E. FOUGERA & CO., A… CGMP Deviations: Out-of-specification (OOS) low viscosity results were obtained during routine stability testing (CRT) for Ciclopirox… |
| Jul 7, 2011 | Class III | D-914-2011 | DESOXIMETASONE CREAM USP 0.25%, a) 15 grams per tube, NDC 0168-0180-15, b) 60 grams per… Impurities/Degradation Products: Out of Specification (OOS) results, for a degradantion product were obtained during routine stability… |
| May 3, 2011 | Class III | D-916-2011 | DESONIDE OINTMENT, 0.05%,15 grams per tube, Rx only, E. FOUGERA & CO., A division of… Container Leakage: Out-of-specification results for weight loss. |
| Mar 30, 2011 | Class III | D-990-2011 | DIFLORASONE DIACETATE OINTMENT USP, 0.05%, NET WT 30 grams, Rx only, a) fougera label, NDC… Product lacks stability: Out-of-specification (OOS) result for low viscosity obtained during stability testing. |
FDA record score
8 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
15 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Inspection classified VAI | Aug 10, 2022 | 6 x 0.6 | 3.6 |
| Inspection classified VAI | Aug 8, 2019 | 6 x 0.25 | 1.5 |
| Inspection classified VAI | May 29, 2018 | 6 x 0.25 | 1.5 |
| Class II recall D-0612-2017, this FEI as the recalling firm | Mar 2, 2017 | 4 x 0.25 | 1 |
| Inspection classified VAI | Nov 10, 2016 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Dec 23, 2014 | 10 years or older, so it adds no points | 0 |
| Class II recall D-0245-2015, this FEI as the recalling firm | Aug 28, 2014 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Oct 31, 2013 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Nov 16, 2012 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Jun 15, 2012 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Feb 9, 2011 | 10 years or older, so it adds no points | 0 |
| Class II recall D-515-2010, this FEI as the recalling firm | Mar 30, 2010 | 10 years or older, so it adds no points | 0 |
| Class II recall D-504-2010, this FEI as the recalling firm | Mar 19, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Jan 12, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Feb 6, 2009 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Inspection citations | Nov 17, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 17, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 17, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 17, 2026 | Newest record Nov 16, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Fougera Pharmaceuticals, LLC as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Fougera Pharmaceuticals, LLC yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Fougera Pharmaceuticals LLC
- Location
- Melville, NY (US)
- Registration Expires
- Dec 31, 2027
- Operations
- ANALYSIS
- Source
- decrs